Clinical Trials

Gulf Coast Retina Specialists 


Jason M. Handza, D.O.

Board Certified Ophthalmologist

Fellowship Trained Vitreoretinal Surgeon

​​​

    What is a Clinical Trial? It is basically a medical research study that is used to evaluate the safety and effectiveness of a new procedure, medication, or device to prevent, diagnose, or treat an eye disease or disorder (www.nei.nih.gov/). 



Principal Investigator,  Apellis Pharmaceuticals Protocol APL2-303,"A Phase III, Multicenter, Randomized, Double-Masked, Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham-Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)"2018. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Principal Investigator, DRCR Protocol AG,"Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction "2018. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Principal Investigator,  Clearside Biomedical Protocol CLS1003-302,"Topaz: A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal Cls-TA In Combination With An Intravitreal Anti-Vegf Agent In Subjects With Retinal Vein Occlusion"2018. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Principal Investigator, DRCR Protocol AD,"PROMINENT- Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate versus Placebo"2017. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Principal Investigator, DRCR Protocol AC,"Randomized Trial of Aflibercept versus Bevacizumab for Treatment of Central-Involved Diabetic Macular Edema."2017. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Principal Investigator, DRCR Protocol AB, "Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy."2017. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Principal Investigator, DRCR Protocol W,"Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk. "2017. Eye Associates of Pinellas, Pinellas Park, Florida.

 

Co-Investigator, Genentech Protocol #FVF2587g (ANCHOR), “A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 [Ranibizumab] Compared with Verteporfin (VisudyneTM) Photodynamic Therapy in Subjects with Predominately Classic Subfoveal Neovascular Age-Related Macular Degeneration.”  2003-2004. University of South Florida Eye Institute, Tampa, Florida.

 

Co-Investigator, Genentech Protocol #FVF2598g (MARINA), “A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 [Ranibizumab] in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration.”  2003-2004. University of South Florida Eye Institute, Tampa, Florida.

 

Co-Investigator, Genentech Protocol #FVF2508g (Extended), “An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 [Ranibizumab] in Subjects with Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study.” 2003-2004.  University of South Florida Eye Institute, Tampa, Florida.

 

Co-Investigator, Genentech Protocol #FVF2428g (FOCUS), “A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 [Ranibizumab] in Combination with Verteporfin (VisudyneTM) Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration.”   2003-2004.  University of South Florida Eye Institute, Tampa, Florida.

 

Co-Investigator, Eli Lilly Protocol #B7A-MC-MBCM, “Protein Kinase C β Inhibitor – Diabetic Retinopathy Study 2 (PKC-DRS2) A Phase 3 Clinical Trial.” 2003-2004.  University of South Florida Eye Institute, Tampa, Florida.